Erasca Investors Reminded of Lead Plaintiff Deadline in Class Action Lawsuit
Investors who sustained losses exceeding $100,000 in Erasca securities during the class period have been reminded of the deadline for lead plaintiff applications in a securities class action lawsuit.
A reminder has been issued to investors who purchased or acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025, and April 26, 2026, that the deadline to file lead plaintiff applications in a class action lawsuit is August 10, 2026. The lawsuit alleges that Erasca and certain executives failed to disclose material information and made misleading statements during this period.
The core of the complaint centers on the company's product candidate ERAS-0015, a pan-RAS molecular glue for RAS-mutated solid tumors. Plaintiffs claim that preclinical data for ERAS-0015 was based on improper comparisons to Revolution Medicines, Inc., potentially infringing on patent and trade secret protections. This alleged misrepresentation, according to the suit, lacked a reasonable basis.
The securities class action is pending in the United States District Court for the Southern District of California. Investors who experienced losses of over $100,000 and meet the class period criteria are advised to consult with legal counsel. Kahn Swick & Foti, LLC has made attorneys available to discuss legal options without charge.
ClaimsFiler, a shareholder information service, is providing information on this case and other securities class actions, assisting investors in navigating the claims process.